David Paul Morris | Bloomberg | Getty Images
Pfizer‘s vaccine that protects infants from respiratory could receive Food and Drug Administration approval by the tip of this summer.
Pfizer on Tuesday said the FDA is reviewing the vaccine on an expedited basis. The agency is anticipated to make a call on whether to clear the shot in August, just before respiratory virus season.
The only-dose vaccine is run to expectant moms within the late second to 3rd trimester of their pregnancy. The antibodies triggered by the shot are passed to the fetus, and protect infants against RSV from birth through the primary six months of life, once they are most vulnerable.
The vaccine was 82% effective at stopping severe disease from RSV in newborns throughout the first 90 days of life, in line with data from Pfizer’s clinical trial. The shot was about 70% effective throughout the first six months of the child’s life.
No vaccine to guard against RSV exists now. Infants younger than 6 months are also too young to receive most shots beneficial by the Centers for Disease Control and Prevention.
RSV is the leading reason behind hospitalization for infants within the U.S., in line with epidemiologists. Just about all children catch RSV by the point they’re 2 years old, and normally the virus causes a light, cold-like illness. But infants face the next risk of severe disease.
RSV could cause inflammation of the small airways within the lungs and pneumonia. Infants hospitalized with RSV often need oxygen support and IV fluids, and will have to be placed on a ventilator to support their respiratory.
Symptoms in infants with RSV can include irritability, decreased activity and appetite, and pauses in respiratory lasting longer than 10 seconds. The virus doesn’t all the time cause a fever.
RSV exploded last fall as the general public largely stopped wearing masks and practicing social distancing because the Covid-19 pandemic eased. Many children didn’t catch RSV throughout the pandemic as a consequence of the general public health measures, and as a consequence didn’t have immunity from prior infection as people began socializing again, in line with CDC officials.
Hospitals struggled to maintain up with large numbers of sick babies and kids last fall. The Kid’s Hospital Association called the RSV surge “unprecedented” and asked the Biden administration to declare a public health emergency throughout the peak in November.
Join CNBC’s Healthy Returns on March 29, where we’ll convene a virtual gathering of CEOs, scientists, investors and innovators within the health-care space to reflect on the progress made today to reinvent the long run of drugs. Plus, we’ll have an exclusive rundown of the very best investment opportunities in biopharma, health tech and managed care. Learn more and register today:Â http://bit.ly/3DUNbRo
